At a glance
ClinicalIndex Comparison Record- ✓Age 12 to 15 months
- ✓No active liver disease
- ✓No prior hepatitis A infection
- ✓No prior measles, mumps, rubella, or varicella infection
- ✕Prior hepatitis A vaccination
- ✕Prior measles, mumps, rubella, or varicella vaccination
- ✕Any immune deficiency
- ✕Allergy to vaccine components
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open, Randomized, Multicenter Study of the Safety, Tolerability, & Immunogenicity of VAQTA™ Given Concomitantly With PROQUAD™ and PREVNAR™ in Healthy Children 12 Months of Age
In Brief
A Phase 4 clinical trial evaluating Comparator: VAQTA™ (Hepatitis A vaccine), Comparator: ProQuad™ (Measles, Mumps, Rubella and Varicella vaccine), and 1 other intervention for Hepatitis A Virus. Completed, enrolled 653 participants.
Detailed Summary
Hepatitis A vaccine will be given either alone or together with measles, mumps, rubella, and varicella vaccine and pneumococcal 7-valent conjugate vaccine at the first dose and together with measles, mumps, rubella, and varicella \[Oka/Merck\] virus vaccine at the second dose. Immunogenicity and safety data will be collected after each dose of vaccine.
Study Details
Timeline
Interventions
VAQTA™ 0.5 mL injection
ProQuad™ 0.5 mL injection
Prevnar™ 0.5 mL injection